HRS-9821

Primary objectives: To evaluate the safety and tolerability of single-dose and multiple-dose nebulized inhalation of HRS-9821 suspension in healthy subjects and COPD patients. Secondary objectives: 1. To compare the bronchodilator effect and duration of single-dose and multiple-dose nebulized inhalation of HRS-9821 suspension in healthy subjects and COPD patients, as well as other spirometry examination indicators compared with placebo. 2. To evaluate the pharmacokinetics (PK) of HRS-9821 suspension in healthy subjects and COPD patients after single-dose nebulized inhalation. 3. To evaluate the drug concentration in the lung epithelial lining fluid and the theoretical intracellular concentration of bronchoalveolar lavage fluid cells after a single nebulized inhalation of HRS-9821 suspension in healthy subjects by bronchoalveolar lavage (BAL).